BRPI1008850A2 - [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase - Google Patents

[1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase

Info

Publication number
BRPI1008850A2
BRPI1008850A2 BRPI1008850A BRPI1008850A BRPI1008850A2 BR PI1008850 A2 BRPI1008850 A2 BR PI1008850A2 BR PI1008850 A BRPI1008850 A BR PI1008850A BR PI1008850 A BRPI1008850 A BR PI1008850A BR PI1008850 A2 BRPI1008850 A2 BR PI1008850A2
Authority
BR
Brazil
Prior art keywords
triazolo
pyridines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
BRPI1008850A
Other languages
English (en)
Inventor
Caroline Leriche
David Middlemiss
Eric Auclair
Jacques Le Roux
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008850(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of BRPI1008850A2 publication Critical patent/BRPI1008850A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
BRPI1008850A 2009-02-13 2010-02-09 [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase BRPI1008850A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09360013 2009-02-13
PCT/EP2010/051556 WO2010092041A1 (en) 2009-02-13 2010-02-09 [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI1008850A2 true BRPI1008850A2 (pt) 2016-03-15

Family

ID=42229029

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008850A BRPI1008850A2 (pt) 2009-02-13 2010-02-09 [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase

Country Status (24)

Country Link
US (1) US20120041195A1 (pt)
EP (1) EP2396324A1 (pt)
JP (1) JP2012517971A (pt)
KR (1) KR20110116160A (pt)
CN (1) CN102317288A (pt)
AR (1) AR075411A1 (pt)
BR (1) BRPI1008850A2 (pt)
CA (1) CA2751517A1 (pt)
CL (1) CL2011001947A1 (pt)
CO (1) CO6420343A2 (pt)
CR (1) CR20110386A (pt)
DO (1) DOP2011000248A (pt)
EA (1) EA201101188A1 (pt)
EC (1) ECSP11011250A (pt)
HN (1) HN2011002095A (pt)
IL (1) IL214426A0 (pt)
MX (1) MX2011008549A (pt)
NI (1) NI201100151A (pt)
NZ (1) NZ594508A (pt)
PE (1) PE20120110A1 (pt)
SG (1) SG173610A1 (pt)
TN (1) TN2011000379A1 (pt)
WO (1) WO2010092041A1 (pt)
ZA (1) ZA201105896B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459258B (zh) * 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TW201204723A (en) * 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
MX348783B (es) * 2011-04-21 2017-06-28 Bayer Ip Gmbh Triazolopiridinas.
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
CA2867061A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
EP2872506A1 (en) 2012-07-10 2015-05-20 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
DK3008062T3 (en) 2013-06-11 2017-06-12 Bayer Pharma AG PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES
KR20220104786A (ko) * 2019-11-22 2022-07-26 메드샤인 디스커버리 아이엔씨. Dna-pk 억제제로서의 피리미도피롤 스피로 화합물 및 이의 유도체

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
MXPA02003140A (es) 1999-11-22 2002-09-30 Warner Lambert Co Quinazolinas y su uso para la inhibicion de las enzimas cinasa dependientes del ciclin.
KR101075812B1 (ko) * 2002-12-18 2011-10-25 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서의 트리아졸로피리다진
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
JP2007509059A (ja) 2003-10-16 2007-04-12 カイロン コーポレイション 癌の処置のためのＲａｆキナーゼのインヒビターとしての、２，６−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン
EP1809614B1 (en) 2004-04-08 2014-05-07 TargeGen, Inc. Benzotriazine inhibitors of kinases
CA2578283A1 (en) 2004-08-25 2006-03-02 Targegen, Inc. Heterocyclic compounds and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
JP2008533166A (ja) 2005-03-16 2008-08-21 ターゲジェン インコーポレーティッド ピリミジン化合物および使用法
EP1878727A4 (en) 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
JP2008543775A (ja) 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
US20070129364A1 (en) * 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US8883820B2 (en) * 2006-08-30 2014-11-11 Cellzome Ltd. Triazole derivatives as kinase inhibitors
EP2076513A1 (en) * 2006-10-20 2009-07-08 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
US20100216767A1 (en) 2006-12-22 2010-08-26 Mina Aikawa Quinazolines for pdk1 inhibition
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010014005A (es) * 2008-06-20 2011-02-15 Genentech Inc Compuestos de triazolopiridina inhibidores de jak y los metodos.
US20100035875A1 (en) * 2008-06-20 2010-02-11 Bing-Yan Zhu Triazolopyridine jak inhibitor compounds and methods
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010189A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
TW201010977A (en) * 2008-08-12 2010-03-16 Takeda Pharmaceutical Amide compound
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法

Also Published As

Publication number Publication date
JP2012517971A (ja) 2012-08-09
CL2011001947A1 (es) 2012-03-16
AR075411A1 (es) 2011-03-30
CR20110386A (es) 2011-12-02
CA2751517A1 (en) 2010-08-19
DOP2011000248A (es) 2011-10-31
MX2011008549A (es) 2011-12-06
NZ594508A (en) 2013-12-20
EA201101188A1 (ru) 2012-04-30
IL214426A0 (en) 2011-09-27
SG173610A1 (en) 2011-09-29
CO6420343A2 (es) 2012-04-16
KR20110116160A (ko) 2011-10-25
US20120041195A1 (en) 2012-02-16
ECSP11011250A (es) 2011-10-31
NI201100151A (es) 2012-10-03
WO2010092041A1 (en) 2010-08-19
CN102317288A (zh) 2012-01-11
ZA201105896B (en) 2012-03-28
HN2011002095A (es) 2014-01-06
TN2011000379A1 (en) 2013-03-27
PE20120110A1 (es) 2012-02-20
EP2396324A1 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
BRPI1008850A2 (pt) [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
HRP20171724T1 (hr) Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze
DOP2011000388A (es) Carboxamidas 5-fenilo-[1,2,4] triazolo [1,5-a] piridina-2-il como inhibidores jak
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BR112012002110A2 (pt) derivados de pirrolo[1,2-b]piridazina como inibidores de janus cinase
EP2608669A4 (en) NEW PYRAZOLO- [1,5-A-] PYRIMIDINE DERIVATIVES AS ANTI-MTOR HEMMER
CO7071124A2 (es) Pirazolo[1,5-a]piridina sustituida como inhibidores del receptor de cinasa tropomiosina (trk)
BRPI0908433A2 (pt) pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase
ES2598358T8 (es) Derivados de quinolina como inhibidores de PI3K quinasa
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
CO6801740A2 (es) Inhibidores de quinasa relacionados con pirrolo[2,3-d]pirimidina tropomiosina
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BR112012029437A2 (pt) derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk
BR112012029405A2 (pt) compostos macrocíclicos como inibidores de trk quinase
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
BRPI0809998A2 (pt) Composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina cinase
BRPI1012108A2 (pt) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrila como inibidores de jak
HK1158947A1 (en) Macrocyclic pyrimidines as protein kinase inhibitors
BRPI1015038A2 (pt) derivados espiro azacíclicos como inibidores de hsl
BR112013012965A2 (pt) derivados de imidazo (1,2-b] piridazina e imidazo [4, 5 -b] piridina como inibidores de jak
BRPI1011066A2 (pt) "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
BR112013022917A2 (pt) derivados 3,4-dihidro-pirrolo[1,2-a]pirazino-1-ilamina úteis como inibidores de beta-secretase (bace)
CO6811848A2 (es) Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas
IL224903A (en) Imidzo [c – 5,4] quinolines as DNA inhibitors
EP2525659A4 (en) PYRAZOLO [1,5-A] PYRIMIDINES COMPOUNDS AS MTOR INHIBITORS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.